Product Information Sheet for NR-52019

Recombinant Respiratory Syncytial Virus, A2 Expressing Red Fluorescent Protein (RFP) (rrRSV-BNI)

Catalog No. NR-52019

For research use only. Not for use in humans.

Contributor:
Mark E. Peeples, Professor, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA

Manufacturer:
BEI Resources

Product Description:
Virus Classification: *Pneumoviridae, Orthopneumovirus, Human orthopneumovirus*
Species: Respiratory Syncytial Virus
Strain/Isolate: A2
Note: The RFP designation on the vial label is incorrect. The correct RFP designation is rrRSV-BN1.
Original Source: Recombinant respiratory syncytial virus, A2 expressing red fluorescent protein (RFP; rrRSV-BNI) was developed using a historical strain of RSV, A2, originally isolated in the 1950s in the USA.[1]
Comments: The complete genome of RSV, A2 has been sequenced (GenBank: KT992094).

Recombinant RSV, A2 expressing RFP (rrRSV-BNI) was developed by recombination using the P. Collins system. It is useful for drug development, such as screening of antiviral drugs, studying RSV infection *in vitro* and *in vivo* animal model, developing assays for identification of neutralizing antibodies and viral assays for vaccine development.[1]

Material Provided:
Each vial contains approximately 1.0 mL of cell lysate and supernatant from *Homo sapiens* epithelial carcinoma cells infected with RSV, A2 expressing RFP (rrRSV-BNI).

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:
NR-52019 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:
Host: *Homo sapiens* epithelial carcinoma cells (HEp-2; ATCC® CCL-23™)
Growth Medium: Dulbecco's Modified Eagle's Medium containing Earle's Balanced Salt Solution (ATCC® 30-2002™) with 25 mM HEPES (Gibco; 15630-080, supplemented with 10% fetal bovine serum (ATCC® 30-2020™), and 1X Glutamax (Gibco 35050-061) or equivalent
Infection: Cells should be 70% to 90% confluent
Incubation: 3 to 5 days at 37°C and 5% CO_2
Cytopathic Effect: Syncytia formation and cell disruption

Citation:
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Recombinant Respiratory Syncytial Virus, A2 Expressing Red Fluorescent Protein (RFP) (rrRSV-BNI), NR-52019."

Biosafety Level: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

References:

1. Peeples, M. E., Personal Communication.
2. Hallak, L. K., et al. "Iduronic Acid-Containing Glycosaminoglycans on Target Cells are Required for Efficient Respiratory Syncytial Virus Infection." Virology 271 (2000): 264-275. PubMed: 10860881.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898